ATMI, Inc. has completed a two-year, multi-million dollar expansion of its Bloomington, MN manufacturing facility. The expansion establishes a North American hub for the production, marketing and development of ATMI’s Integrity single-use technologies for biopharmaceutical and other life science applications.
The added capabilities double the company’s worldwide capacity for the fabrication of ATMI LifeSciences Integrity product line of 2-D and 3-D transfer, storage, mixing and bioreactor vessels, while adding supply chain contingency through a dual-manufacturing capability shared with existing bioprocess manufacturing plant in Hoegaarden, Belgium. The expansion also adds a variety of new jobs from assembly and testing to lab supervision, manufacturing engineering and product engineering.
“We have developed this world class facility in direct response to the growing needs of our North American customers for additional single-use bioprocess vessel manufacturing capacity. Creating a copy-exact of our Belgian facility for change management and supply chain security reasons also helped us to quickly replicate cGMP procedures,” commented Doug Neugold, ATMI chief executive officer and president. “With advanced vessel design, 100% integrity testing and extensive quality controls, we continue to apply our experience in semiconductor manufacturing to our life science business.”
The expansion features a 2,500 sq.-ft. Class 1000 cleanroom with Class 100 work areas, as well as a new demonstration and applications lab and a separate product development lab. The expansion is ISO 9001 certified and cGMP compliant.